Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 9/20 | 0.42 |
| ▸ | PDE1A | P54750 | 3/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | F5 | P12259 | 1/20 | 0.36 |
| ▸ | BRSK2 | Q8IWQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16812489 | 1.00 | HPGDS (0.45) | HPGDSKMT2APDE1BPDE1APDE1C | |
| SCHEMBL16794721 | 1.00 | HPGDS (0.45) | HPGDSKMT2APDE1BPDE1APDE1C | |
| SCHEMBL16794647 | 0.94 | PDE1B (0.37) | HPGDSKMT2APDE1BPDE1CF10 | |
| SCHEMBL16794653 | 0.91 | CNR2 (0.41) | NTRK1F10BRD4 | |
| SCHEMBL16812491 | 0.90 | YAP1 (0.43) | HPGDSKMT2AF10 | |
| SCHEMBL16794701 | 0.90 | YAP1 (0.41) | HPGDSKMT2APDE1BF10 | |
| SCHEMBL16812485 | 0.87 | HPGDS (0.41) | HPGDSKMT2APDE1BF10 | |
| SCHEMBL31161333 | 0.84 | SSTR3 (0.35) | KMT2APDE1BNTRK1F10 | |
| SCHEMBL31161788 | 0.84 | TYK2 (0.37) | PDE1BF10 | |
| SCHEMBL16812488 | 0.84 | TYK2 (0.40) | KMT2APDE1BF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3080131-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3080131-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | Bristol-Myers Squibb Company (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | TYK2, IFNAR1, JAK3 | HPGDS 2012/4885KMT2A 1271/4885PDE1B 1789/4885 |
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | TYK2, IFNG, IFNAR1 | HPGDS 2119/4885KMT2A 1273/4885PDE1B 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.